Results 181 to 190 of about 58,529 (279)

Kinetic and thermodynamic characterisation of HIV-protease inhibitors against E35D↑G↑S mutant in the South African HIV-1 subtype C protease. [PDF]

J Enzyme Inhib Med Chem, 2019
Maseko S, Padayachee E, Maphumulo S, Govender T, Sayed Y, Maguire G, Lin J, Naicker T, Baijnath S, Gerhardus KH.   +9 more
europepmc   +1 more source

Clinical outcome after coronary events in patients treated with HIV-protease inhibitors [PDF]

, 2000
Jean-Jacques Monsuez
openalex   +1 more source

The INAVA mRNA in Extracellular Vesicles Activates Normal Ovarian Fibroblasts by Phosphorylation–Ubiquitylation Crosstalk of HMGA2

Advanced Science, Volume 12, Issue 25, July 3, 2025.
Ovarian cancer‐derived extracellular vesicles (EVs) transfer INAVA mRNA to normal ovarian fibroblasts (NOFs). Translated INAVA protein inhibits HMGA2 phosphorylation‐dependent ubiquitylation and proteasomal degradation, promoting NOF activation.
Lingkai Gu, Zhangjin Shen, Shizhen Shen, Conghui Wang, Yuwan Liu, Xinyi Wei, Mengxia Zheng, Jiaxin Gu, Xiaojing Chen, Yi Sun, Junfen Xu, Yan Lu, Weiguo Lu   +12 more
wiley   +1 more source

New cytochalasins: Synthetic studies of a novel HIV-1 protease inhibitor

, 1996
Randall W. Hungate, Jenny L. Chen, Ken E. Starbuck, Sally A. Macaluso, Robert S. Rubino   +4 more
openalex   +1 more source

Dynamic Cap‐Mediated Substrate Access and Potent Inhibitor Design of Monkeypox Virus I7L Protease

Advanced Science, Volume 12, Issue 26, July 10, 2025.
The first crystal structure of MPXV I7L protease, revealing its unique dimeric form is resolved. The structures and MD simulations uncovered a dynamic cap region that regulates substrate access to the active site. The structural basis of substrate recognition and the catalytic mechanism are elucidated, which led to the development of a FRET‐based assay
Haixia Su, Guoqing Wu, Muya Xiong, Yuhang Wang, Junyuan Cao, Mengyuan You, Yingchun Xiang, Tianqing Nie, Minjun Li, Gengfu Xiao, Leike Zhang, Qiang Shao, Yechun Xu   +12 more
wiley   +1 more source

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers. [PDF]

Antimicrob Agents Chemother, 2019
Feng HP, Caro L, Fandozzi C, Chu X, Guo Z, Talaty J, Panebianco D, Dunnington K, Du L, Hanley WD, Fraser IP, Mitselos A, Denef JF, De Lepeleire I, de Hoon JN, Vandermeulen C, Marshall WL, Jumes P, Huang X, Martinho M, Valesky R, Butterton JR, Iwamoto M, Yeh WW.   +23 more
europepmc   +1 more source

Screening of Inhibitors of HIV-1 Protease Using anEscherichia coliCell Assay

, 1997
J. Büttner, Klaus Dornmair, Hans J. Schramm   +2 more
openalex   +1 more source

HIV Protease Inhibitors Stimulate Hepatic Triglyceride Synthesis [PDF]

, 2000
James M. Lenhard, Dallas K. Croom, James E. Weiel, Deborah A. Winegar   +3 more
openalex   +1 more source

Trypstatin as a Novel TMPRSS2 Inhibitor with Broad‐Spectrum Efficacy against Corona and Influenza Viruses

Advanced Science, Volume 12, Issue 25, July 3, 2025.
Trypstatin, a 61‐amino acid Kunitz‐type protease inhibitor derived from human Bikunin, potently inhibits TMPRSS2 and related proteases. It blocks spike‐ and hemagglutinin‐mediated entry of multiple respiratory viruses in vitro reduces SARS‐CoV‐2 replication in human airway cultures, and lowers viral load and symptoms in infected hamsters, demonstrating
Jan Lawrenz, Lukas Wettstein, Armando Rodríguez Alfonso, Rayhane Nchioua, Pascal von Maltitz, Dan Pascal Jean Albers, Fabian Zech, Julie Vandeput, Lieve Naesens, Giorgio Fois, Veronika Neubauer, Nico Preising, Emilia Schmierer, Yasser Almeida‐Hernandez, Moritz Petersen, Ludger Ständker, Sebastian Wiese, Peter Braubach, Manfred Frick, Eberhard Barth, Daniel Sauter, Frank Kirchhoff, Elsa Sanchez‐Garcia, Annelies Stevaert, Jan Münch   +24 more
wiley   +1 more source

Update: Enzymatische Synthese für industrielle Anwendungen

Angewandte Chemie, Volume 137, Issue 27, July 1, 2025.
Die Biokatalyse hat sich zu einer nachhaltigen und wettbewerbsfähigen Alternative zur herkömmlichen chemischen Synthese entwickelt und ermöglicht die enzymbasierte Herstellung nicht nur von chemischen Grundstoffen, sondern auch von (nicht natürlichen) Aminosäuren, (seltenen) Zuckern und synthetischen Nukleotiden.
Thomas Bayer, Shuke Wu, Radka Snajdrova, Kai Baldenius, Uwe T. Bornscheuer   +4 more
wiley   +1 more source